Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Fairmount Funds Management LLC

Q4 2024 · 13F-HR

Fairmount Funds Management LLCholdings as filed

Filed 2025-02-14 · accession 0001104659-25-014003

$1.01B
Reported value
17
Positions
2024-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
05464T104AXSMAXSOME THERAPEUTICS INC$124.3M12.4%1,468,983CommonSOLE
670703107NUVLNUVALENT INC$103.1M10.3%1,317,664CommonSOLE
00773J202SYRESPYRE THERAPEUTICS INC$93.5M9.30%4,018,101CommonSOLE
03770N101APGEAPOGEE THERAPEUTICS INC$92.8M9.23%2,048,647CommonSOLE
80706P103SRRKSCHOLAR ROCK HLDG CORP$84.8M8.43%1,962,953CommonSOLE
29337E102ELVNENLIVEN THERAPEUTICS INC$72.1M7.16%3,202,798CommonSOLE
92790C104VRDNVIRIDIAN THERAPEUTICS INC$66.1M6.57%3,445,813CommonSOLE
687604108ORKAORUKA THERAPEUTICS INC$65.4M6.50%3,371,922CommonSOLE
252828108DNTHDIANTHUS THERAPEUTICS INC$58.9M5.85%2,700,691CommonSOLE
19240Q201COGTCOGENT BIOSCIENCES INC$48.6M4.83%6,225,641CommonSOLE
G52694109KNSAKINIKSA PHARMACEUTICALS INTL$43.4M4.32%2,194,341CommonSOLE
23954D109DAWNGBXDAY ONE BIOPHARMACEUTICALS INC$39.3M3.91%3,103,448CommonSOLE
04635X102CATBUSDASTRIA THERAPEUTICS INC$31.8M3.16%3,554,129CommonSOLE
032724106ANABANAPTYSBIO INC$24.1M2.39%1,816,466CommonSOLE
055477103BCAXBICARA THERAPEUTICS INC$22.4M2.22%1,284,169CommonSOLE
45719W205IKTINHIBIKASE THERAPEUTICS INC$19.9M1.98%6,125,000CommonSOLE
98937L105ZBIOZENAS BIOPHARMA INC$15.5M1.54%1,892,806CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.